Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest announcement is out from Regencell Bioscience ( (RGC) ).
On June 2, 2025, Regencell Bioscience Holdings Limited announced a 38-for-one forward stock split, approved by its board of directors, to enhance market liquidity and accessibility for its shares. The stock split, effective for shareholders of record on June 12, 2025, will distribute additional shares on June 13, 2025, with trading on a post-split basis commencing on June 16, 2025, pending Nasdaq approval. This move is expected to increase the company’s outstanding shares without altering its authorized share capital or trading symbol, requiring no action from shareholders.
More about Regencell Bioscience
Regencell Bioscience Holdings Limited is an early-stage bioscience company focusing on the research, development, and commercialization of Traditional Chinese Medicine for treating neurocognitive disorders, particularly Attention Deficit Hyperactivity Disorder and Autism Spectrum Disorder. The company aims to lead the market in natural and holistic treatments for neurological disorders globally.
Average Trading Volume: 685,214
Technical Sentiment Signal: Buy
Current Market Cap: $11.41B
For a thorough assessment of RGC stock, go to TipRanks’ Stock Analysis page.